Seagen Inc.
A single plant registered with the FDA to make drugs for the US market. Below is where it is and the drugs whose FDA labels list this site as performing a manufacturing step — so if this plant has a problem, these are the products that could be affected.
- Country
- United States
- Registered address
- 21823 30th Drive SE, Bothell, Washington (WA) 98021, United States (USA)
- Operations here
- analysis
- FDA identifiers
- FEI 3002781621 · DUNS 028484371
FDA inspection history
Outcomes of closed FDA inspections at this site (drug and biologic program areas).
- VAIDrug Quality Assurance2025-05-13
- NAIBioresearch Monitoring2024-11-01
- NAIDrug Quality Assurance2024-05-02
- NAIDrug Quality Assurance2020-01-24
- NAIBioresearch Monitoring2019-10-04
- NAIDrug Quality Assurance2018-01-05
- VAIBioresearch Monitoring2017-05-01
- VAIDrug Quality Assurance2015-06-09
- VAIBioresearch Monitoring2013-03-20
- VAIDrug Quality Assurance2013-03-20
- VAIBioresearch Monitoring2011-07-19
- VAIDrug Quality Assurance2011-05-19
Drugs this plant is listed as making
1 distinct drugs across 1 products name this site in their FDA label.
- brentuximab vedotinSeagen Inc.
Sources:the establishment's name, address, and country from FDA's Drug Establishments Current Registration Site (DECRS); the drug-to-facility links from DailyMed SPL drug labels, matched by the facility's DUNS number; inspection outcomes from the FDA Data Dashboard, matched by FEI; shortage status from FDA's drug shortage database. More on how this is built. Educational only.